Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company securing Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its lead cancer therapy, PTX-100. The designation applies to cutaneous T-cell lymphoma (CTCL), including both mycosis fungoides and Sézary syndrome subtypes.
McDonnell explained that patients in Europe currently have fewer treatment options compared to those in the US, noting: "This is an opportunity to provide another option for them. So they should be pretty happy." The ODD unlocks key benefits for the company, including ten years of data exclusivity following potential approval in Europe.
He also highlighted the strategic advantages of the designation, saying it improves the company’s position for regulatory discussions with the EMA and increases attractiveness to potential partners.
#PrescientTherapeutics #PTX100 #CTCL #OrphanDrug #EMAapproval #BiotechStocks #CancerTreatment #JamesMcDonnell #MycosisFungoides #SézarySyndrome #ProactiveInvestors #BiotechNews